Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model

PLoS One. 2014 Feb 28;9(2):e90441. doi: 10.1371/journal.pone.0090441. eCollection 2014.

Abstract

This study aimed to determine whether the addition of an aminoglycoside to a ß-lactam antibiotic increases the antimicrobial effect during the early phase of Gram-negative severe sepsis/septic shock. A porcine model was selected that considered each animal's individual blood bactericidal capacity. Escherichia coli, susceptible to both antibiotics, was given to healthy pigs intravenously during 3 h. At 2 h, the animals were randomized to a 20-min infusion with either cefuroxime alone (n = 9), a combination of cefuroxime+tobramycin (n = 9), or saline (control, n = 9). Blood samples were collected hourly for cultures and quantitative polymerase chain reaction (PCR). Bacterial growth in the organs after 6 h was chosen as the primary endpoint. A blood sample was obtained at baseline before start of bacterial infusion for ex vivo investigation of the blood bactericidal capacity. At 1 h after the administration of the antibiotics, a second blood sample was taken for ex vivo investigation of the antibiotic-induced blood killing activity. All animals developed severe sepsis/septic shock. Blood cultures and PCR rapidly became negative after completed bacterial infusion. Antibiotic-induced blood killing activity was significantly greater in the combination group than in the cefuroxime group (p<0.001). Growth of bacteria in the spleen was reduced in the two antibiotic groups compared with the controls (p<0.01); no difference was noted between the two antibiotic groups. Bacterial growth in the liver was significantly less in the combination group than in the cefuroxime group (p<0.05). High blood bactericidal capacity at baseline was associated with decreased growth in the blood and spleen (p<0.05). The addition of tobramycin to cefuroxime results in increased antibiotic-induced blood killing activity and less bacteria in the liver than cefuroxime alone. Individual blood bactericidal capacity may have a significant effect on antimicrobial outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology
  • Bacterial Load
  • Cefuroxime / pharmacology*
  • Critical Care
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Escherichia coli / drug effects
  • Escherichia coli / growth & development
  • Escherichia coli / pathogenicity
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / microbiology
  • Female
  • Humans
  • Immunity, Innate
  • Liver / drug effects
  • Liver / microbiology
  • Male
  • Sepsis / drug therapy*
  • Sepsis / microbiology
  • Spleen / drug effects
  • Spleen / microbiology
  • Swine
  • Tobramycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Cefuroxime
  • Tobramycin

Grants and funding

The R&D funds of Uppsala University Hospital, the Swedish Research Council (2010–3826) and the Olinder-Nielsen Family fund contributed with financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.